Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Andrew Eugene Hendifar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2079-9177; OpenAlex author ID A5003116709, A5027630636, A5112511787, A5125667824. Sources: ClinicalTrials.gov.

Their work

Papers
81 (first author 9, last author 19)
Trials
7 (principal investigator on 7)
Grants
0
Labs led
1
Collaborators
246
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper, 1 trial · 2016: 4 papers · 2017: 7 papers, 1 trial · 2018: 5 papers · 2019: 8 papers · 2020: 8 papers, 2 trials · 2021: 8 papers, 1 trial · 2022: 9 papers, 1 trial · 2023: 8 papers, 1 trial · 2024: 10 papers · 2025: 4 papers · 2026: 7 papers

Papers 50 of 81

  1. Young Women With Pancreatic Cancer: A High-Risk Group for Demoralization. Last author DOI 10.1002/pon.70601↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 Glut… Co-author DOI 10.1038/s43018-026-01225-z↗
  4. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  5. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  6. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  7. Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630. First author DOI 10.3390/cancers18050789↗
  8. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. Co-author DOI 10.1016/j.hpb.2025.07.012↗
  9. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  10. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. Last author DOI 10.1200/po-24-00684↗
  11. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. First author DOI 10.3390/cancers17040630↗
  12. Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation T… Co-author DOI 10.1016/j.adro.2024.101471↗
  13. High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program. Co-author DOI 10.1016/j.hpb.2024.05.005↗
  14. Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery. Co-author DOI 10.1038/s41698-024-00521-0↗
  15. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s43018-023-00697-7↗
  16. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/ajcp/aqae038↗
  17. Keratin 17 modulates the immune topography of pancreatic cancer. Co-author DOI 10.1186/s12967-024-05252-1↗
  18. Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study. Last author DOI 10.14309/ctg.0000000000000719↗
  19. A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy. Last author DOI 10.18632/oncotarget.28659↗
  20. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support Co-author DOI 10.20944/preprints202401.0727.v1↗
  21. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analy… Co-author DOI 10.3390/cancers16050971↗
  22. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  23. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001-2018. Co-author DOI 10.1053/j.gastro.2023.01.022↗
  24. Response of Locally Advanced Pancreatic Cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical … Co-author DOI 10.1097/mpa.0000000000002236↗
  25. Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma. Last author DOI 10.21037/jgo-23-12↗
  26. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity Co-author DOI 10.21203/rs.3.rs-3647514/v1↗
  27. Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol. Last author DOI 10.3390/biomedicines11051392↗
  28. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000-2018. Co-author DOI 10.3390/cancers15030870↗
  29. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. First author DOI 10.3390/cancers15113020↗
  30. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  31. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-022-19401-3↗
  32. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-022-23619-6↗
  33. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
  34. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation. Co-author DOI 10.1097/mpa.0000000000002059↗
  35. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  36. Multitasking dynamic contrast enhanced magnetic resonance imaging can accurately differentiate chronic pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.1007134↗
  37. Gut microbiome and pancreatic cancer cachexia: An evolving relationship. Co-author DOI 10.4251/wjgo.v14.i7.1218↗
  38. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7039↗
  39. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experienc… Co-author DOI 10.1002/cam4.4257↗
  40. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. Last author DOI 10.1002/jcsm.12799↗
  41. Symptom Management in Pancreatic Cancer. Last author DOI 10.1007/s11864-020-00801-4↗
  42. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  43. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. Co-author DOI 10.1200/po.20.00494↗
  44. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗
  45. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. First author DOI 10.3389/fonc.2021.678070↗
  46. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Co-author DOI 10.3390/cancers13215510↗
  47. Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mrm.28167↗
  48. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  49. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literat… First author DOI 10.1097/mpa.0000000000001507↗
  50. Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1177/1756284820964319↗

Trials 7

  1. Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Principal investigator NCT05766748↗
  2. A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma Principal investigator NCT05336266↗
  3. Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer Principal investigator NCT05078775↗
  4. Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain Principal investigator NCT04034745↗
  5. Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency Principal investigator NCT04098237↗
  6. Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia Principal investigator NCT03207724↗
  7. Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients Principal investigator NCT02400398↗

Closest collaborators

The 25 strongest of 246 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Arsen Osipov · 31 shared papers, 2016–2026 · strength 5.05
  2. Jun Gong · 30 shared papers, 2016–2026 · strength 4.60
  3. Simon K. Lo · 18 shared papers, 2014–2026 · strength 2.56
  4. Stephen Jacob Pandol · 17 shared papers, 2014–2026 · strength 2.52
  5. Srinivas Gaddam · 12 shared papers, 2020–2026 · strength 1.99
  6. Nicholas N. Nissen · 16 shared papers, 2014–2025 · strength 1.94
  7. Brent K. Larson · 10 shared papers, 2019–2026 · strength 1.67
  8. Richard Tuli · 19 shared papers, 2014–2020 · strength 1.59
  9. Gillian K. Gresham · 7 shared papers, 2020–2026 · strength 1.32
  10. Natalie Moshayedi · 8 shared papers, 2022–2026 · strength 1.28
  11. Veronica Placencio-Hickok · 9 shared papers, 2019–2024 · strength 1.23
  12. Andrew L. Coveler · 5 shared papers, 2021–2026 · strength 1.22
  13. Neil A. Bhowmick · 6 shared papers, 2022–2026 · strength 1.05
  14. Hayato Muranaka · 6 shared papers, 2022–2026 · strength 1.05
  15. Abrahm Levi · 5 shared papers, 2023–2026 · strength 1.01
  16. Paul E. Oberstein · 5 shared papers, 2018–2026 · strength 0.99
  17. Matthew Ebia · 4 shared papers, 2023–2025 · strength 0.95
  18. Lynn McCormick Matrisian · 8 shared papers, 2017–2025 · strength 0.94
  19. Emanuel F. Petricoin · 7 shared papers, 2018–2025 · strength 0.93
  20. Michael Jon Pishvaian · 7 shared papers, 2017–2025 · strength 0.86
  21. Debiao Li · 6 shared papers, 2020–2024 · strength 0.84
  22. Davendra P. S. Sohal · 6 shared papers, 2018–2026 · strength 0.69
  23. Megan Philippa Hitchins · 3 shared papers, 2019–2024 · strength 0.64
  24. Vincent M. Chung · 7 shared papers, 2017–2026 · strength 0.63
  25. Michelle Guan · 5 shared papers, 2019–2022 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.